OBJECTIVE: The most commonly used dose for prostate cancer stereotactic body radiotherapy (SBRT) is 5 × 7.25 Gy. The aim of this study was to evaluate the dosimetric feasibility of a 5 × 9 Gy SBRT regimen while still limiting the dose to the urethra to 5 × 7.25 Gy. This dosimetric study is part of the groundwork for a future Phase III randomized trial. METHODS: The prostate, the urethra and the tumors were delineated on 20 dosimetric CT-scans with MRI-registration. The planning target volume (PTVp) was defined as a 5 mm expansion (3 mm posteriorly) of the prostate. The planning at risk volume (PRVu) was defined as a 2 mm expansion of the urethra. The tumors were delineated on the MRI (GTVt) and a 3 mm-margin was added to create a tumoral planning target volume (PTVt). IMRT plans were optimized to deliver 5 × 9 Gy to the PTVp, limiting the dose to the PRVu to 5 × 7.25 Gy. Results are presented using average (range) values. RESULTS: PTVp doses were D98% = 36.2 Gy (35.6-36.8), D2% = 46.9 Gy (46.5-47.5) and mean dose = 44.1 Gy (43.8-44.5). The dose to the PRVu was within tolerance limits for all 20 patients: V34.4Gy = 99.8% (99.2-100) and D5% = 38.7 Gy (38.6-38.8). Dose coverage of PTV-PRVu was D95% = 40.6 Gy (40.5-40.9), D5% = 46.6 Gy (46.2-47.2) and mean dose = 44.6 Gy (44.3-44.9). Dose to the PTVt reached 44.6 Gy (41.2-45.9). Doses to the OAR were respected, except V36Gy ≤1 cc for the rectum. CONCLUSION: A SBRT dose-escalation to 5 × 9 Gy on the prostate while sparing the urethra + 2 mm at 36.25 Gy is feasible without compromising dose coverage to the tumor. This radiation regimen will be used for a Phase-III trial. ADVANCES IN KNOWLEDGE: In prostate SBRT, dose optimization on the urethra is feasible and could decrease urinary toxicities.
OBJECTIVE: The most commonly used dose for prostate cancer stereotactic body radiotherapy (SBRT) is 5 × 7.25 Gy. The aim of this study was to evaluate the dosimetric feasibility of a 5 × 9 Gy SBRT regimen while still limiting the dose to the urethra to 5 × 7.25 Gy. This dosimetric study is part of the groundwork for a future Phase III randomized trial. METHODS: The prostate, the urethra and the tumors were delineated on 20 dosimetric CT-scans with MRI-registration. The planning target volume (PTVp) was defined as a 5 mm expansion (3 mm posteriorly) of the prostate. The planning at risk volume (PRVu) was defined as a 2 mm expansion of the urethra. The tumors were delineated on the MRI (GTVt) and a 3 mm-margin was added to create a tumoral planning target volume (PTVt). IMRT plans were optimized to deliver 5 × 9 Gy to the PTVp, limiting the dose to the PRVu to 5 × 7.25 Gy. Results are presented using average (range) values. RESULTS: PTVp doses were D98% = 36.2 Gy (35.6-36.8), D2% = 46.9 Gy (46.5-47.5) and mean dose = 44.1 Gy (43.8-44.5). The dose to the PRVu was within tolerance limits for all 20 patients: V34.4Gy = 99.8% (99.2-100) and D5% = 38.7 Gy (38.6-38.8). Dose coverage of PTV-PRVu was D95% = 40.6 Gy (40.5-40.9), D5% = 46.6 Gy (46.2-47.2) and mean dose = 44.6 Gy (44.3-44.9). Dose to the PTVt reached 44.6 Gy (41.2-45.9). Doses to the OAR were respected, except V36Gy ≤1 cc for the rectum. CONCLUSION: A SBRT dose-escalation to 5 × 9 Gy on the prostate while sparing the urethra + 2 mm at 36.25 Gy is feasible without compromising dose coverage to the tumor. This radiation regimen will be used for a Phase-III trial. ADVANCES IN KNOWLEDGE: In prostate SBRT, dose optimization on the urethra is feasible and could decrease urinary toxicities.
Authors: D W Nathan Kim; L Chinsoo Cho; Christopher Straka; Alana Christie; Yair Lotan; David Pistenmaa; Brian D Kavanagh; Akash Nanda; Patrick Kueplian; Jeffrey Brindle; Susan Cooley; Alida Perkins; David Raben; Xian-Jin Xie; Robert D Timmerman Journal: Int J Radiat Oncol Biol Phys Date: 2014-07-01 Impact factor: 7.038
Authors: Anna M E Bruynzeel; Shyama U Tetar; Swie S Oei; Suresh Senan; Cornelis J A Haasbeek; Femke O B Spoelstra; Anna H M Piet; Philip Meijnen; Marjolein A B Bakker van der Jagt; Tamara Fraikin; Berend J Slotman; Reindert J A van Moorselaar; Frank J Lagerwaard Journal: Int J Radiat Oncol Biol Phys Date: 2019-08-13 Impact factor: 7.038
Authors: Michael J Zelefsky; Marisa Kollmeier; Sean McBride; Melissa Varghese; Borys Mychalczak; Richard Gewanter; Madhur K Garg; Laura Happersett; Debra A Goldman; Isaac Pei; Mary Lin; Zhigang Zhang; Brett W Cox Journal: Int J Radiat Oncol Biol Phys Date: 2019-01-04 Impact factor: 7.038
Authors: Raquibul Hannan; Vasu Tumati; Xian-Jin Xie; L Chinsoo Cho; Brian D Kavanagh; Jeffrey Brindle; David Raben; Akash Nanda; Susan Cooley; D W Nathan Kim; David Pistenmaa; Yair Lotan; Robert Timmerman Journal: Eur J Cancer Date: 2016-03-29 Impact factor: 9.162
Authors: Maud Jaccard; Thomas Zilli; Angèle Dubouloz; Lluís Escude; Sandra Jorcano; Nadine Linthout; Samuel Bral; Wilko Verbakel; Anna Bruynzeel; Mikko Björkqvist; Heikki Minn; Lev Tsvang; Zvi Symon; Joana Lencart; Angelo Oliveira; Zeynep Ozen; Ufuk Abacioglu; Juan María Pérez-Moreno; Carmen Rubio; Michel Rouzaud; Raymond Miralbell Journal: Int J Radiat Oncol Biol Phys Date: 2020-06-12 Impact factor: 7.038
Authors: Jeffrey Vainshtein; Eyad Abu-Isa; Karin B Olson; Michael E Ray; Howard M Sandler; Dan Normolle; Dale W Litzenberg; Kathryn Masi; Charlie Pan; Daniel A Hamstra Journal: Radiat Oncol Date: 2012-06-09 Impact factor: 3.481
Authors: Jean-Bernard Delobel; Khemara Gnep; Juan David Ospina; Véronique Beckendorf; Ciprian Chira; Jian Zhu; Alberto Bossi; Taha Messai; Oscar Acosta; Joël Castelli; Renaud de Crevoisier Journal: PLoS One Date: 2017-06-22 Impact factor: 3.240
Authors: Leonard N Chen; Simeng Suy; Sunghae Uhm; Eric K Oermann; Andrew W Ju; Viola Chen; Heather N Hanscom; Sarah Laing; Joy S Kim; Siyuan Lei; Gerald P Batipps; Keith Kowalczyk; Gaurav Bandi; John Pahira; Kevin G McGeagh; Brian T Collins; Pranay Krishnan; Nancy A Dawson; Kathryn L Taylor; Anatoly Dritschilo; John H Lynch; Sean P Collins Journal: Radiat Oncol Date: 2013-03-13 Impact factor: 3.481
Authors: Mark E Hwang; Mark Mayeda; Maria Liz; Brenda Goode-Marshall; Lissette Gonzalez; Carl D Elliston; Catherine S Spina; Oscar A Padilla; Sven Wenske; Israel Deutsch Journal: Radiat Oncol Date: 2019-08-02 Impact factor: 3.481